1 Min Read
June 16(Reuters) - Seikagaku Corp
* Says it announces the start of phase II study of SI-613 in patients with osteoarthritis of the knee, in the U.S.
Source text in Japanese:goo.gl/F8pM1P
Further company coverage: (Beijing Headline News)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.